23.90Open23.90Pre Close0 Volume179 Open Interest300.00Strike Price0.00Turnover49.72%IV-9.10%PremiumDec 20, 2024Expiry Date46.93Intrinsic Value100Multiplier19DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9338Delta0.0055Gamma5.34Leverage Ratio-0.0758Theta-0.0757Rho-4.99Eff Leverage0.0720Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet